{
  "id": 7175076,
  "title": "No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy",
  "url": "https://urgent.news/2026/09/13/no-survival-bump-in-metastatic-nsclc-with-addition-of-adc-to",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-13T21:00:00.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/iaslc/122983"
  },
  "original_language": "en",
  "account": "A recent randomized trial, EVOKE-03, did not find improved survival in metastatic non-small cell lung cancer (NSCLC) patients when the antibody-drug conjugate sacituzumab govitecan (Trodelvy) was added to immunotherapy, reported lead investigator Giannis Mountzios, MD, PhD. Median progression-free survival (PFS) did not reach the required statistical significance, despite an improvement from 7.7 months with pembrolizumab alone to 11.8 months with the combination. The study also showed a slight advantage for the control arm in overall survival (OS), but this difference was not statistically significant. An interim analysis revealed more treatment-emergent adverse events in the sacituzumab group, including serious, treatment-discontinuation, and fatal events. The results indicate that sacituzumab govitecan plus pembrolizumab adds a chemotherapy-like effect without a lasting survival benefit. Pembrolizumab monotherapy remains the standard for PD-L1-high groups, and future trials should focus on overall survival with proper biomarker selection and stratification.",
  "summary": "(MedPage Today) -- Survival in metastatic non-small cell lung cancer (NSCLC) did not improve with the addition of the antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) to immunotherapy, a large randomized trial showed. Median progression...",
  "key_points": [
    "No survival improvement with sacituzumab govitecan + pembrolizumab in metastatic NSCLC",
    "Median PFS improved from 7.7 to 11.8 months with combination",
    "Slight OS advantage for control arm not statistically significant"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}